Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The timing of initiation to immunotherapy, either with the first cycle of chemotherapy or within 21 days of diagnosis, does not significantly affect outcomes in ES-SCLC. | Image Credit: Bonsales - stock.adobe.com
Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

June 12th 2025

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com
Novel Biomarkers May Inform Prognosis in SCLC

June 6th 2025

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com
Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

May 12th 2025

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.
Continuing Medical Education
View All
June 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Network of patients
March 15th 2023

Racial, Ethnic, Socioeconomic Disparities Identified Among Patients With Cachexia at NSCLC Diagnosis

Rose McNulty
A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups.
FDA
March 8th 2023

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

Chris Ryan
The FDA approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small-cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.
Annual Lung Cancer Screening Adherence Poor After Initial Screening, Study Finds
March 4th 2023

Annual Lung Cancer Screening Adherence Poor After Initial Screening, Study Finds

Rose McNulty
Adherence to annual lung cancer screening was only 22.3% among more than 1 million patients who underwent baseline screening between 2015 and 2019, a study published in the journal CHEST found.
Composite image of lungs and a doctor
March 2nd 2023

Cemiplimab Plus Chemotherapy Approaches EU Approval for PD-L1–Positive NSCLC

Kristi Rosa
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non–small-cell lung cancer with PD-L1 expression of 1% or higher.
Image of genetic code with biomarker highlighted
February 23rd 2023

Study Identifies FGFR3 as Biomarker for Superior Outcomes in NSCLC

Jared Kaltwasser
Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC).
Image depicting genetic research
February 20th 2023

Immune Signature Could Help Tailor Treatment Choices in NSCLC

Jared Kaltwasser
The authors identified 2 subgroups with non–small cell lung cancer (NSCLC) who had different responses to common cancer therapies.
Image of a radiologist looking at a lung cancer image
February 16th 2023

Real-World Data Show SCLC Outcomes Remain Grim

Jared Kaltwasser
The authors say newer treatment options for small cell lung cancer (SCLC) may lead to improvement in this area of high unmet need.
Image of an oncologist pointing out lung cancer
February 13th 2023

Surgical Quality Metric Adherence Substantially Improves Outcomes in Early NSCLC

Jared Kaltwasser
Overall survival and recurrence-free survival showed substantial improvement when physicians more closely followed quality recommendations for non–small cell lung cancer (NSCLC).
Image of healthy and diseased lungs
February 7th 2023

Randomized Prospective Trial Suggests AI Improves Lung Cancer Screening

Jared Kaltwasser
Artificial intelligence (AI) improved detection of actionable lung nodules without leading to higher rates of false positives, the study found.
NCCN Guideline Update Reflects Rise of Precision Options in NSCLC
February 5th 2023

NCCN Guideline Update Reflects Rise of Precision Options in NSCLC

Mary Caffrey
The latest updates in non–small cell lung cancer (NSCLC) cover recommendations for diagnostics, staging, when to use biomarker testing, sequencing of therapeutic options, and the addition of new treatments.
COTA Joins Multistakeholder Clinical Research Data Sharing Alliance
January 31st 2023

COTA Joins Multistakeholder Clinical Research Data Sharing Alliance

Rose McNulty
The real-world oncology data and analytics company COTA has joined the Clinical Research Data Sharing Alliance, a nonprofit consortium that aims to accelerate progress in cancer therapy development.
Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests
January 29th 2023

Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests

Rose McNulty
A new study estimates that prescription of standard-of-care non–small-cell lung cancer (NSCLC) therapies is lower than expected in Medicaid programs, with significant variation between states.
Timothy Murphy, MD, Rocky Mountain Cancer Centers
January 26th 2023

Dr Timothy Murphy Discusses How COVID-19 Has Affected Lung Cancer Screening

Julia Bonavitacola Laura Joszt, MA
Timothy Murphy, MD, FACP, practice president of Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the effect of the COVID-19 pandemic on screening for lung cancer.
Image of lung cancer research
January 23rd 2023

PD-L1 Scoring in NSCLC Varies Significantly

Jared Kaltwasser
This new study has found different labs followed similar practices, but the way they scored patients varied significantly.
Timothy Murphy, MD, Rocky Mountain Cancer Centers
January 20th 2023

Dr Timothy Murphy Discusses Racial Disparities in Lung Cancer Screenings

Julia Bonavitacola Laura Joszt, MA
Timothy Murphy, MD, FACP, current practice president at Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the current state of lung cancer screenings.
Colorful lung graphic
January 17th 2023

Potential Molecular Mechanisms That Increase COVID-19 Risk in Lung Cancer Highlighted

Jared Kaltwasser
This experimental research suggests the expression levels of certain genes might help explain why people with lung cancer often have more severe cases of COVID-19.
Image of genetic code
January 10th 2023

Investigators Find Potential Biomarker for Platinum-Based Chemotherapy Response in NSCLC

Jared Kaltwasser
Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.
Image of Clostridioides difficile bacteria
January 9th 2023

Concurrent Antibiotics, Steroids Raise CDI Risk in People With Lung Cancer Receiving EGFR-TKIs

Jared Kaltwasser
The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.
Lab workers preparing samples
January 5th 2023

Tumor-Associated Autoantibodies Demonstrate Promise as Immunotherapy Biomarkers in NSCLC

Julia Bonavitacola
The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.
Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC
January 5th 2023

Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC

Julia Bonavitacola
This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).
Hilary Tindle, MD, MPH, Associate Professor of Medicine, Vanderbilt University
December 27th 2022

Dr Hilary Tindle Discusses NMR and Precision Approaches in Cancer Care

Pearl Steinzor
Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke about the use of precision medicine approaches, such as the nicotine metabolite ratio (NMR), to improve outcomes for patients with lung cancer.
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022

Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC

Mary Caffrey Hayden E. Klein
Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Hilary Tindle, MD, MPH, Associate Professor of Medicine, Vanderbilt University
December 20th 2022

Dr Hilary Tindle: Tobacco Nation's High Rates of Lung Cancer

Pearl Steinzor
Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke on increased rates of smoking and lung cancer within a particular region of the United States called "Tobacco Nation."
graphic indicating genetic code
December 9th 2022

Switch to NGS Would Lead to More Targeted NSCLC Care, but May Not Lower Costs

Jared Kaltwasser
The study, based on care in Japan, found patients would be more quickly referred for targeted therapy.
picture of cannabis
December 7th 2022

Cannabis Used With ICIs Appears to Have No Impact on NSCLC Outcomes

Jared Kaltwasser
Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.
Image of lung cancer
November 29th 2022

Afatinib Outperforms First-Generation EGFR-TKIs in NSCLC With Uncommon EGFR Mutations

Jared Kaltwasser
The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.
Lungs and stethoscope
November 22nd 2022

Early Lung Cancer Screening Program Dramatically Increases Survival Rates

Pearl Steinzor
A recent study stresses the importance of routine CT screening for improving lung cancer survival outcomes.
Lungs
November 16th 2022

Despite Improvements in Lung Cancer Screening, Increased Efforts Still Needed to Address Disparities

Justina Petrullo
The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.
image of research
November 13th 2022

Doubling Women’s Lung Cancer Research Funding Would Generate Major Returns, Study Says

Jared Kaltwasser
Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.
FDA approved cemiplimab plus chemotherapy for NSCLC
November 9th 2022

FDA Approves Cemiplimab Plus Chemotherapy as First-line NSCLC Treatment

Allison Inserro
The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.
<12345678
...
10>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo